According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “
ADMS has been the subject of several other reports. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the company a buy rating in a report on Tuesday, May 28th. Mizuho reissued a buy rating and issued a $37.00 price objective on shares of Revance Therapeutics in a report on Wednesday, April 24th. Finally, ValuEngine lowered Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $18.91.
Shares of Adamas Pharmaceuticals stock opened at $6.00 on Wednesday. The company has a debt-to-equity ratio of 2.00, a current ratio of 7.03 and a quick ratio of 6.86. Adamas Pharmaceuticals has a fifty-two week low of $4.20 and a fifty-two week high of $29.49. The company has a 50-day moving average price of $5.27.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($1.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.13) by $0.05. The firm had revenue of $11.67 million during the quarter, compared to analyst estimates of $12.78 million. Adamas Pharmaceuticals had a negative return on equity of 122.40% and a negative net margin of 291.22%. Equities research analysts anticipate that Adamas Pharmaceuticals will post -3.77 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA acquired a new position in Adamas Pharmaceuticals in the first quarter valued at approximately $33,000. PNC Financial Services Group Inc. acquired a new position in Adamas Pharmaceuticals in the first quarter valued at approximately $43,000. Advisor Group Inc. boosted its stake in Adamas Pharmaceuticals by 252.0% in the fourth quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 4,510 shares during the period. Barclays PLC boosted its stake in Adamas Pharmaceuticals by 87.6% in the fourth quarter. Barclays PLC now owns 17,387 shares of the specialty pharmaceutical company’s stock valued at $148,000 after acquiring an additional 8,118 shares during the period. Finally, Creative Planning acquired a new position in Adamas Pharmaceuticals in the first quarter valued at approximately $144,000. Institutional investors own 76.68% of the company’s stock.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.